
|Articles|August 1, 2001
- Pharmaceutical Executive-08-01-2001
- Volume 0
- Issue 0
Science-Driven Marketing
Author(s)Wayne Koberstein
That marketing should begin early in product development has become a truism in the pharma industry. But as a statement on its own, it sheds little light. What does it mean to begin? At what point do marketers insert themselves into the process? To what end do they enter where once only scientists trod? And, the ultimate question—which the truism fails to answer—how might their intrusion affect the lives of patients, in trial or thereafter?
Advertisement
Articles in this issue
about 25 years ago
Decision Making at Digital Speedabout 25 years ago
Mergers: Big Pharma Shrinks Someabout 25 years ago
Generics: Streamline and Stimulateabout 25 years ago
Grace Under Fireabout 25 years ago
Get Ready to Merge or Divergeabout 25 years ago
Pharma's Quantum ShuffleAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Significance of FDA’s First Warning Letter for Inappropriate Use of AI
2
Jazz Pharmaceuticals to Acquire Actio Biosciences for $1.32 Billion
3
Generating Commercial Evidence from Agentic Field and Brand Engagement to Accelerate Launch Performance
4
M&A Roundup: Novo Nordisk Enters AI Drug Discovery Partnership with Amazon, Innate Pharma Partners with Sobi, Innovent Enters Commercialization Agreement with Daiichi Sankyo
5




